Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Stacey A Cohen and Dr Arvind Dasari, moderated by Dr Bekaii-Saab, including the following topics: Introduction (0:00) Current and Future Role of Immune Checkpoint Inhibition in the Management of Microsatellite Instability-High/Mismatch Repair Deficient Localized and Locally Advanced Colorectal Cancer (CRC) — Dr Cohen (1:45) Clinical Relevance and Practical Utilization of Molecular Residual Disease Analysis in CRC — Dr Dasari (34:08) Recent Advances in Metastatic CRC: Optimizing Immunotherapy and Other Approaches — Dr Bekaii-Saab (1:00:42) CME information and select publications

Colorectal Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Research To Practice | Oncology Videos

[SPEAKER_A] Well, hello and welcome to Consensus or Controversy: Documenting and Discussing Investigators' Approaches to the Management of Colorectal Cancer. I'm Dr Tanios Bekaii-Saab, and I'll be moderating the meeting today. This is our faculty for today. Dr. Stacey Cohen, professor at the Hutch, and then Dr. Dasari, professor at MD Anderson. And these are contributing clinical investigators that helped answer some of the surveys that we'll be going through. In preparation for this meeting, Research to Practice conducted a survey of this evening's faculty as well as 3 additional contributing investigators, Dr. Faqi, Dr. Lu, and Dr. Saied, which all provided their perspectives on a number of issues related to the management of colorectal cancer. Select results will be discussed during the program. Full results are available to download if interested. And these are the disclosures of each one of the speakers and contributors. This activity is supported by educational grants from Excellaxis, GSK, and Natera, Research to Practice CME Planning Committee members, staff, and reviewers have essentially no relevant financial interest to disclose. This educational activity contains discussions of non-FDA-approved uses of agents and regimens. Please refer to official prescribing information for each product for approved indications. We're going to start with Module 1. And again, we want to thank Dr Cohen for a last-minute covering subject for Dr Sersak, and she will be presenting on Current and Future Role of Immune Checkpoint Inhibition in the Management of Microsatellite, so MSI-high, dMMR localized and locally advanced colorectal cancer. So, Stacey.

[SPEAKER_B] Thank you for inviting me tonight, and I apologize, you're supposed to be hearing from Dr Andrea Sersak tonight, who a lot of this data is from her in addition to her actually making these slides.

Colorectal Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Colorectal Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.